254 886

Cited 14 times in

Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Surrogate Biomarker for Bevacizumab in Colorectal Cancer Liver Metastasis: A Single-Arm, Exploratory Trial

DC Field Value Language
dc.contributor.author김명진-
dc.contributor.author박미숙-
dc.contributor.author신상준-
dc.contributor.author안중배-
dc.date.accessioned2017-10-26T07:44:43Z-
dc.date.available2017-10-26T07:44:43Z-
dc.date.issued2016-
dc.identifier.issn1598-2998-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/152461-
dc.description.abstractPURPOSE: The purpose of this study is to investigate dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and plasma cytokines and angiogenic factors (CAFs) as pharmacodynamic and prognostic biomarkers of bevacizumab monotherapy in colorectal cancer with liver metastasis (CRCLM). MATERIALS AND METHODS: From July 2011 to March 2012, 28 patients with histologically confirmed CRCLM received bevacizumab monotherapy followed by combined FOLFOX therapy. The mean age of the patients was 57 years (range, 30 to 77 years). DCE-MRI (Ktransand IAUC60) was performed at baseline, first follow-up (3 days after bevacizumab monotherapy), and second follow-up (3 days after combined therapy). CAF levels (vascular endothelial growth factor [VEGF], placental growth factor [PlGF], and interleukin-8) were assessed on the same days. Progression-free survival (PFS) time distributions were summarized using the Kaplan-Meier method and compared using log-rank tests. RESULTS: The median PFS period was 11.2 months. Ktrans, IAUC60, VEGF, and PlGF values on the first follow-up day were significantly different compared with baseline values. No differences were observed on the second follow-up day. A > 40% decrease in Ktrans from baseline to first follow-up was associated with a longer PFS (hazard ratio, 0.349; 95% confidence interval, 0.133 to 0.912; p=0.032). Changes in CAFs did not show correlation with PFS time. CONCLUSION: DCE-MRI parameters and CAFs are pharmacodynamic biomarkers of bevacizumab for CRCLM. In our study, change in Ktrans at 3 days after bevacizumab monotherapy was a favorable prognostic factor; however, the value of CAFs as a prognostic biomarker was not found.-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish, Korean-
dc.publisherOfficial journal of Korean Cancer Association-
dc.relation.isPartOfCANCER RESEARCH AND TREATMENT-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHBevacizumab/administration & dosage-
dc.subject.MESHBiomarkers, Tumor/blood-
dc.subject.MESHColorectal Neoplasms/blood-
dc.subject.MESHColorectal Neoplasms/diagnostic imaging*-
dc.subject.MESHColorectal Neoplasms/drug therapy*-
dc.subject.MESHColorectal Neoplasms/pathology-
dc.subject.MESHContrast Media/administration & dosage-
dc.subject.MESHDisease-Free Survival-
dc.subject.MESHFemale-
dc.subject.MESHHumans-
dc.subject.MESHInterleukin-8/blood-
dc.subject.MESHKaplan-Meier Estimate-
dc.subject.MESHLiver Neoplasms/blood-
dc.subject.MESHLiver Neoplasms/diagnostic imaging*-
dc.subject.MESHLiver Neoplasms/drug therapy*-
dc.subject.MESHLiver Neoplasms/secondary-
dc.subject.MESHMagnetic Resonance Imaging*-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHPlacenta Growth Factor/blood-
dc.subject.MESHVascular Endothelial Growth Factor A/blood-
dc.titleDynamic Contrast-Enhanced Magnetic Resonance Imaging as a Surrogate Biomarker for Bevacizumab in Colorectal Cancer Liver Metastasis: A Single-Arm, Exploratory Trial-
dc.typeArticle-
dc.publisher.locationKorea-
dc.contributor.collegeCollege of Medicine-
dc.contributor.departmentDept. of Radiology-
dc.contributor.googleauthorYeo-Eun Kim-
dc.contributor.googleauthorBio Joo-
dc.contributor.googleauthorMi-Suk Park-
dc.contributor.googleauthorSang Joon Shin-
dc.contributor.googleauthorJoong Bae Ahn-
dc.contributor.googleauthorMyeong-Jin Kim-
dc.identifier.doi10.4143/crt.2015.374-
dc.contributor.localIdA01463-
dc.contributor.localIdA02105-
dc.contributor.localIdA02262-
dc.contributor.localIdA00426-
dc.relation.journalcodeJ00453-
dc.identifier.eissn2005-9256-
dc.relation.journalsince2001~-
dc.identifier.pmid26987390-
dc.relation.journalbefore~2001 Journal of the Korean Cancer Research Association (대한암학회지)-
dc.subject.keywordBevacizumab-
dc.subject.keywordColorectal neoplasms-
dc.subject.keywordDynamic contrast enhanced-magnetic resonance imaging-
dc.contributor.alternativeNameKim, Myeong Jin-
dc.contributor.alternativeNamePark, Mi Sook-
dc.contributor.alternativeNameShin, Sang Joon-
dc.contributor.alternativeNameAhn, Joong Bae-
dc.contributor.affiliatedAuthorPark, Mi-Suk-
dc.contributor.affiliatedAuthorShin, Sang Joon-
dc.contributor.affiliatedAuthorAhn, Joong Bae-
dc.contributor.affiliatedAuthorKim, Myeong Jin-
dc.citation.volume48-
dc.citation.number4-
dc.citation.startPage1210-
dc.citation.endPage1221-
dc.identifier.bibliographicCitationCANCER RESEARCH AND TREATMENT, Vol.48(4) : 1210-1221, 2016-
dc.date.modified2017-10-24-
dc.identifier.rimsid48664-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Radiology (영상의학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.